Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 4
1989 4
1990 3
1991 4
1992 1
1993 4
1994 3
1995 5
1996 2
1997 5
1998 4
1999 7
2000 8
2001 7
2002 6
2003 2
2004 3
2005 3
2006 8
2007 8
2008 9
2009 6
2010 14
2011 15
2012 18
2013 15
2014 25
2015 15
2016 17
2017 18
2018 6
2019 8
2020 18
2021 11
2022 11
2023 13
2024 8
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Results by year

Filters applied: . Clear all
Page 1
Management of freezing of gait - mechanism-based practical recommendations.
Tosserams A, Fasano A, Gilat M, Factor SA, Giladi N, Lewis SJG, Moreau C, Bloem BR, Nieuwboer A, Nonnekes J. Tosserams A, et al. Among authors: factor sa. Nat Rev Neurol. 2025 Jun;21(6):327-344. doi: 10.1038/s41582-025-01079-6. Epub 2025 Apr 1. Nat Rev Neurol. 2025. PMID: 40169855 Review.
Movement disorders emergencies.
Munhoz RP, Scorr LM, Factor SA. Munhoz RP, et al. Among authors: factor sa. Curr Opin Neurol. 2015 Aug;28(4):406-12. doi: 10.1097/WCO.0000000000000212. Curr Opin Neurol. 2015. PMID: 26110802 Review.
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Anderson KE, et al. Among authors: factor sa. Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28. Lancet Psychiatry. 2017. PMID: 28668671 Clinical Trial.
Lurasidone-Induced Tardive Syndrome.
Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA. Tripathi R, et al. Among authors: factor sa. Mov Disord Clin Pract. 2019 Jul 24;6(7):601-604. doi: 10.1002/mdc3.12812. eCollection 2019 Sep. Mov Disord Clin Pract. 2019. PMID: 31538095 Free PMC article.
The LRRK2 p.L1795F variant causes Parkinson's disease in the European population.
Lange LM, Levine K, Fox SH, Marras C, Ahmed N, Kuznetsov N, Vitale D, Iwaki H, Lohmann K, Marsili L, Espay AJ, Bauer P, Beetz C, Martin J, Factor SA, Higginbotham LA, Chen H, Leonard H, Nalls MA, Mencacci NE, Morris HR, Singleton AB, Klein C, Blauwendraat C, Fang ZH; Global Parkinson’s Genetics Program (GP2). Lange LM, et al. Among authors: factor sa. NPJ Parkinsons Dis. 2025 Mar 25;11(1):58. doi: 10.1038/s41531-025-00896-2. NPJ Parkinsons Dis. 2025. PMID: 40133296 Free PMC article.
299 results